Ed Silverman from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 6 days ago STAT+: Up and down the ladder: The latest comings and goings - 9 days ago STAT+: Pharmalittle: We’re reading about FDA plans to ban a cold med; Eisai Alzheimer’s drug sales, and more - 9 days ago STAT+: AstraZeneca says China has detained a senior executive - 11 days ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago STAT+: Pharmalittle: We’re reading about compounded Wegovy, pharmacies suing GoodRx, and more - 11 days ago STAT+: Pharmacies sue GoodRx and PBMs over ‘illegal’ reimbursement fees - 12 days ago STAT+: Pharmalittle: We’re reading about Medicaid coverage of obesity drugs, a death in a sickle cell trial, and more - 12 days ago STAT+: Pharmalittle: We’re reading about a weight loss pill, the FDA warning a compounder, and more - 13 days ago STAT+: Up and down the ladder: The latest comings and goings - 16 days ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 16 days ago STAT+: To mitigate drug shortages, a new study suggests looking at Canada - 17 days ago STAT+: Two generic drugmakers to pay $49 million to settle price-fixing charges - 17 days ago STAT+: Teva fined $503 million for disparaging a rival and using patents to thwart competition - 17 days ago STAT+: Helsinki Declaration says researchers must disclose trial results on a timely basis - 20 days ago STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more - 20 days ago STAT+: A drug may cause problems with chemotherapies in cancer patients with obesity. Many doctors are in the dark - 21 days ago STAT+: Up and down the ladder: The latest comings and goings - 23 days ago STAT+: Pharmalittle: We’re reading about FDA oversight of shortages, AstraZeneca threats, and more - 23 days ago STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 24 days ago STAT+: Pharmalittle: We’re reading about drug shortages, what drugmakers didn’t tell Alzheimer’s trial patients and more - 24 days ago STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - 27 days ago STAT+: Catalent tries to reassure customers about its deal with Novo Holdings - 28 days ago STAT+: Sales from controversial drug discount program rose to $63 billion last year - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Pharmalittle: We’re reading about a new CVS chief, obesity meds cutting overdoses, and more - about 1 month ago STAT+: Consumer and labor groups urge FTC to block Catalent sale to Novo Holdings - about 1 month ago STAT+: Pharmalittle: We’re reading about doctors powering telehealth GLP-1 scripts, an FDA hold on a Novavax shot, and more - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 2 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 2 months ago STAT+: FDA scolds AbbVie over ‘misleading’ TV ad for a migraine pill featuring Serena Williams - 2 months ago STAT+: Pharmalittle: We’re reading about a Novo weight loss study, a GSK vaccine failure, and more - 2 months ago STAT+: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more - 2 months ago STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more - 2 months ago STAT+: U.S. agency slaps down a J&J plan to switch payments for 340B hospitals - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more - 3 months ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - 3 months ago STAT+: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more - 3 months ago STAT+: Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants? - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about a Covid-flu shot setback, mpox vaccine supplies, and more - 3 months ago STAT+: Pharmalittle: We’re reading about FDA rejecting MDMA; a nasal spray for allergic reactions, and more - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about a California bill to restrain PBMs, a U.K. trade group scolding Novo, and more - 3 months ago STAT+: Pharmalittle: We’re reading about a CVS deal with Illinois, a Pfizer hemophilia therapy, and more - 4 months ago STAT+: CVS and its PBM agree to pay $45 million to Illinois for failing to pass drug rebates - 4 months ago STAT+: U.S. Patent Office software mistakes extend patent life for drugs and need to be fixed, researchers say - 4 months ago
2	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago
3	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago
4	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago
5	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago
6	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 24 days ago
7	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 24 days ago